Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches
出版年份 2016 全文链接
标题
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 27, Issue 9, Pages 1706-1712
出版商
Oxford University Press (OUP)
发表日期
2016-05-24
DOI
10.1093/annonc/mdw216
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy
- (2015) A. S. McDaniel et al. CANCER RESEARCH
- UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas
- (2015) S. Q. Wong et al. CANCER RESEARCH
- Releasing the Brakes on Cancer Immunotherapy
- (2015) Dan R. Littman CELL
- A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G
- (2015) Edgardo D. Carosella et al. EUROPEAN UROLOGY
- EAU Guidelines on Penile Cancer: 2014 Update
- (2015) Oliver W. Hakenberg et al. EUROPEAN UROLOGY
- Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers
- (2015) Louisa Mezache et al. MODERN PATHOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
- (2015) Brooke E. Howitt et al. JAMA Oncology
- PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics
- (2014) D. Massi et al. ANNALS OF ONCOLOGY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
- (2012) C. Badoual et al. CANCER RESEARCH
- Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung
- (2012) Jennifer M. Boland et al. Clinical Lung Cancer
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started